Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs

ClinicalTrials.gov ID: NCT01527006

Public ClinicalTrials.gov record NCT01527006. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 8:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label Pilot Study With an Extension Phase to Evaluate the Pharmacokinetics, and to Generate Preliminary Safety, Tolerability, and Efficacy of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Pediatric Subjects From 2 to Less Than 12 Years of Age With Epilepsy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is designed to evaluate the pharmacokinetics, efficacy, and safety of perampanel oral suspension on seizure frequency in pediatric participants maintained on one to three stable antiepileptic drugs

Study identification

NCT ID
NCT01527006
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Eisai Inc.
Industry
Enrollment
63 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
2 Years to 11 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2011
Primary completion
Apr 30, 2014
Completion
Mar 31, 2015
Last update posted
Jul 11, 2016

2012 – 2015

United States locations

U.S. sites
23
U.S. states
16
U.S. cities
23
Facility City State ZIP Site status
Not listed Aurora Colorado
Not listed Washington D.C. District of Columbia
Not listed Gulf Breeze Florida
Not listed Jacksonville Florida
Not listed Miami Florida
Not listed Orlando Florida
Not listed Tampa Florida
Not listed Augusta Georgia
Not listed Indianapolis Indiana
Not listed Lexington Kentucky
Not listed Shreveport Louisiana
Not listed Chesterfield Missouri
Not listed Columbia Missouri
Not listed Gibbsboro New Jersey
Not listed Buffalo New York
Not listed Akron Ohio
Not listed Cincinnati Ohio
Not listed Philadelphia Pennsylvania
Not listed Pittsburgh Pennsylvania
Not listed Memphis Tennessee
Not listed San Antonio Texas
Not listed Salt Lake City Utah
Not listed Richmond Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01527006, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 11, 2016 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01527006 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →